Multiple cytokine biomarkers in heart failure

Expert Review of Molecular Diagnostics

Volumn 10, Issue 2, 2010, Pages 147-157

  Vistnes, Maria ^a,b   Christensen, Geir ^a,b   Omland, Torbjørn ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarker; Cytokine; Heart failure; Inflammation; Multiplex

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE;

BIOINFORMATICS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; INFLAMMATION; KNOWLEDGE; MEDICAL TECHNOLOGY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW;

BIOLOGICAL MARKERS; CYTOKINES; HEART FAILURE; HUMANS;

EID: 77949456971     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.3     Document Type: Review

References (78)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323(4), 236-241 (1990).
2. Testa M, Yeh M, Lee P et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 28(4) 964-971 (1996).
3. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27(5), 1201-1206 (1996).
4. Nishimura Y, Inoue T, Nitto T, Morooka T, Node K. Increased interleukin-13 levels in patients with chronic heart failure. Int. J. Cardiol. 131(3), 421-423 (2009).
5. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Okamura H, Iwasaki T. Increased circulating interleukin-18 in patients with congestive heart failure. Heart 88(3), 296-297 (2002).
6. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT. Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 86(6), 707-710 (2000).
7. Aukrust P, Ueland T, Muller F et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97(12), 1136-1143 (1998).
8. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91(11), 988-998 (2002).
9. Bozkurt B, Kribbs SB, Clubb FJ Jr et al. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97(14), 1382-1391 (1998).
10. Hocking DC, Phillips PG, Ferro TJ, Johnson A. Mechanisms of pulmonary edema induced by tumor necrosis factor-a. Circ. Res. 67(1), 68-77 (1990).
11. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 b modulates the growth and phenotype of neonatal rat cardiac myocytes. J. Clin. Invest. 96(2), 1093-1099 (1995).
12. Baumgarten G, Knuefermann P, Mann DL. Cytokines as emerging targets in the treatment of heart failure. Trends Cardiovasc. Med. 10(5), 216-223 (2000).
13. Oppenhheim JJ, Feldman M. Introduction to the role of cytokines in innate and defense and adaptive immunity. In: Cytokine reference. Oppenhheim JJ, Feldman M (Eds). Academic Press, NY, USA, 3-20 (2001).
14. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113(19), 2335-2362 (2006).
15. Biomarkers definitions working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
16. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115(8), 949-952 (2007).
17. Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 358(20), 2148-2159 (2008).
18. Gwechenberger M, Hulsmann M, Berger R et al. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J. Heart Lung Transplant. 23(7), 839-844 (2004).
19. Orus J, Roig E, Perez-Villa F et al. Prognostic value of serum cytokines in patients with congestive heart failure. J. Heart Lung Transplant. 19(5), 419-425 (2000).
20. Rauchhaus M, Doehner W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102(25), 3060-3067 (2000).
21. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16), 2055-2059 (2001).
22. Anker SD, Negassa A, Coats AJ et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin- converting-enzyme inhibitors: an observational study. Lancet 361(9363), 1077-1083 (2003).
23. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur. Heart J. 26(21) 2232-2237 (2005).
24. Leyva F, Anker SD, Godsland IF et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur. Heart J. 19(12), 1814-1822 (1998).
25. Roe MT, Halabi AR, Mehta RH et al. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. Am. Heart J. 153(4), 507-514 (2007).
26. Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107(11), 1486-1491 (2003).
27. Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108(19), 2317-2322 (2003).
28. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342(12), 836-843 (2000).
29. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101(15), 1767-1772 (2000).
30. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
31. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357(22), 2248-2261 (2007).
32. Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372(9645), 1231-1239 (2008).
33. Fonseca C, Morais H, Mota T et al. The diagnosis of heart failure in primary care: value of symptoms and signs. Eur. J. Heart Fail. 6(6), 795-800 (2004).
34. Yamaoka-Tojo M, Tojo T, Inomata T, Machida Y, Osada K, Izumi T. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J. Card. Fail. 8(1), 21-27 (2002).
35. Heymans S, Hirsch E, Anker SD et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 11(2), 119-129 (2009).
36. Torre-Amione G, Kapadia S, Lee J et al. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart. Circulation 93(4), 704-711 (1996).
37. Shioi T, Matsumori A, Kihara Y et al. Increased expression of interleukin-1 b and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ. Res. 81(5), 664-671 (1997).
38. Woldbaek PR, Tonnessen T, Henriksen UL et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc. Res. 59(1), 122-131 (2003).
39. Petretta M, Condorelli GL, Spinelli L et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am. Heart J. 140(6), E28 (2000).
40. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Dehmer GJ. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am. J. Cardiol. 86(9), 913-918 (2000).
41. Recchia FA, Bernstein RD, Sehgal PB, Ferreri NR, Hintze TH. Cytokines are not a requisite part of the pathophysiology leading to cardiac decompensation. Proc. Soc. Exp. Biol. Med. 223(1), 47-52 (2000).
42. Sandek A, Bauditz J, Swidsinski A et al. Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50(16), 1561-1569 (2007).
43. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am. J. Cardiol. 79(10), 1426-1430 (1997).
44. Aker S, Belosjorow S, Konietzka I et al. Serum but not myocardial TNF-a concentration is increased in pacing-induced heart failure in rabbits. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285(2) R463-R469 (2003).
45. Gaertner R, Lepailleur-Enouf D, Gonzalez W et al. Pulmonary endothelium as a site of synthesis and storage of interleukin-6 in experimental congestive heart failure. Eur. J. Heart Fail. 5(4), 435-442 (2003).
46. Mabuchi N, Tsutamoto T, Wada A et al. Relationship between interleukin-6 production in the lungs and pulmonary vascular resistance in patients with congestive heart failure. Chest 121(4), 1195-1202 (2002).
47. Doehner W, Pflaum CD, Rauchhaus M et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur. J. Endocrinol. 145(6), 727-735 (2001).
48. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. b-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101(17), 2103-2109 (2000).
49. Gullestad L, Aukrust P, Ueland T et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol. 34(7), 2061-2067 (1999).
50. Gurlek A, Kilickap M, Dincer I, Dandachi R, Tutkak H, Oral D. Effect of losartan on circulating TNFa levels and left ventricular systolic performance in patients with heart failure. J. Cardiovasc. Risk 8(5), 279-282 (2001).
51. Mann DL. Targeted anticytokine therapy and the failing heart. Am. J. Cardiol. 95(11A), 9C-16C (2005).
52. Gullestad L, Aass H, Fjeld JG et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103(2), 220-225 (2001).
53. Torre-Amione G, Anker SD, Bourge RC et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 371(9608), 228-236 (2008).
54. Myers GL, Rifai N, Tracy RP et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation 110(25), e545-e549 (2004).
55. Friebe A, Volk HD. Stability of tumor necrosis factor a, interleukin 6, and interleukin 8 in blood samples of patients with systemic immune activation. Arch. Pathol. Lab. Med. 132(11), 1802-1806 (2008).
56. Skogstrand K, Ekelund CK, Thorsen P et al. Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples. J. Immunol. Methods 336(1), 78-84 (2008).
57. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-a and leptin. Cytokine 12(11), 1712-1716 (2000).
58. Manolio T. Novel risk markers and clinical practice. N. Engl. J. Med. 349(17), 1587-1589 (2003).
59. Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107(1), 87-92 (2003).
60. May A, Wang TJ. Biomarkers for cardiovascular disease: challenges and future directions. Trends Mol. Med. 14(6), 261-267 (2008).
61. Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathology - taking molecular pathology into a new dimension. Nat. Rev. Clin. Oncol. 6(8), 455-464 (2009).
62. Kellar KL, Iannone MA. Multiplexed microsphere-based flow cytometric assays. Exp. Hematol. 30(11) 1227-1237 (2002).
63. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor a and interleukin 1b are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med. 183(3), 949-958 (1996).
64. Yin WH, Chen JW, Feng AN, Lin SJ, Young S. Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin. Cardiol. 30(8), 397-402 (2007).
65. Niizeki T, Takeishi Y, Kitahara T et al. Combination of conventional biomarkers for risk stratification in chronic heart failure. J. Cardiol. 53(2), 179-187 (2009).
66. Beirne P, Pantelidis P, Charles P et al. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur. Respir. J. 34(6), 1376-1382 (2009).
67. Chen R, Lowe L, Wilson JD et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin. Chem. 45(9), 1693-1694 (1999).
68. Kellar KL, Kalwar RR, Dubois KA, Crouse D, Chafin WD, Kane BE. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry 45(1), 27-36 (2001).
69. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J. Reprod. Immunol. 66(2), 175-191 (2005).
70. Prabhakar U, Eirikis E, Davis HM. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J. Immunol. Methods 260(1-2), 207-218 (2002).
71. Derveaux S, Stubbe BG, Braeckmans K et al. Synergism between particle-based multiplexing and microfluidics technologies may bring diagnostics closer to the patient. Anal. Bioanal. Chem. 391(7), 2453-2467 (2008).
72. Haeberle S, Zengerle R. Microfluidic platforms for lab-on-a-chip applications. Lab Chip 7(9), 1094-1110 (2007).
73. He H, Yuan Y, Wang W, Chiou NR, Epstein AJ, Lee LJ. Design and testing of a microfluidic biochip for cytokine enzyme-linked immunosorbent assay. Biomicrofluidics 3(2), 22401 (2009).
74. Henares TG, Mizutani F, Hisamoto H. Current development in microfluidic immunosensing chip. Anal. Chim. Acta 611(1), 17-30 (2008).
75. Faratian D, Moodie SL, Harrison DJ, Goryanin I. Dynamic computational modeling in the search for better breast cancer drug therapy. Pharmacogenomics 8(12), 1757-1761 (2007).
76. Noble D. Systems biology and the heart. Biosystems 83(2-3), 75-80 (2006).
77. Winslow RL, Cortassa S, Greenstein JL. Using models of the myocyte for functional interpretation of cardiac proteomic data. J. Physiol. 563(Pt 1), 73-81 (2005).
78. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101(21), 1446-1452 (2009).